The shares of the agrochemical company hit 20 percent at Rs 12,809 apiece after the company’s net profit and revenue increased by 514 percent and 9 percent YoY, respectively in Q1FY25.
With a Market capitalization of Rs 5,322 crore, the shares of Bharat Rasayan Ltd were trading at Rs 12,809 per share, increasing around 19.94 percent as compared to the previous closing price of Rs 10,679.30 apiece.
Reason for rise:-
The share of the company has seen positive movement after Bharat Rasayan Ltd’s revenue plummeted by 9 percent on a quarter-on-quarter basis from Rs. 310 crores in Q4FY24 to Rs.282 crores in Q1FY25. Further, revenue magnified by 17 percent yearly from Rs 239 crores in Q1FY24 to Rs. 282 crores in Q1FY25.
Bharat Rasayan Ltd’s net profit decreased by 36 percent on a quarter-on-quarter basis from Rs. 67 crores in Q4FY24 to Rs 43 in Q1FY25. Further, on a year-on-year basis also net profit magnified drastically by 514 percent from Rs 7 crores in Q1FY24 to Rs. 43 crores in Q1FY25.
Also read
Footprint and Capacity:-
Bharat Rasayan Ltd caters to all the pest problems of major crops grown in India including paddy, cotton, soybean, sugarcane, and other crops. The company has a portfolio of over 200 different products registered with the Central Insecticides Board and has 100 brands.
The firm has a nationwide network of around 4,800 dealers and 30,000 supply wholesalers, as well as 26 locations in all functioning states. The firm operates two production facilities in Dahej (Gujarat) and Mokhra (Haryana), which produce a wide range of active ingredients and intermediates. Furthermore, the Dahej Plant has a capacity of 29,200 MT/year, while the Mokhra Plant has a capacity of 4260 MT/year.
Company profile:-
Bharat Rasayan Limited is an India-based firm that produces technical-grade pesticides, formulations, and intermediates. The company offers insecticides such as Zeta Cypermethrin, Alphacypermethrin, Bifenthrin, Cypermethrin, Acetamiprid, Diafenthiuron, Bifnthrin, Fenvalerate, and Permethrin.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
